Global Healthcare Analyst

Tina Banerjee

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/cochlear-ltd" target="_blank" data-smartkarma-citation="entities:918:1" rel="noopener">Cochlear Ltd (COH AU)</a> expects to report FY26 underlying net profit of $435–460M, an 11–17% increase on FY25, up 5–11% on a comparative (cloud adjusted) basis.</li>
<li>The Nucleus Nexa System has been launched in Europe and Asia Pacific in mid-June 2025 and will be launched in the U.S. by the end of Q1FY26.</li>
<li>The company expects strong FY26 revenue growth in developed markets from the launch of the new Nucleus Nexa implant, with overall revenue and earnings growth weighted to the second half.</li>
</ul>



Cochlear Ltd (COH AU) expects to report FY26 underlying net profit of $435–460M, an 11–17% increase on FY25, up 5–11% on a comparative (cloud adjusted) basis.
The Nucleus Nexa System has been launched in Europe and Asia Pacific in mid-June 2025 and will be launched in the U.S. by the end of Q1FY26.
The company expects strong FY26 revenue growth in developed markets from the launch of the new Nucleus Nexa implant, with overall revenue and earnings growth weighted to the second half.


Cochlear Ltd (COH AU): Earnings Recovery to Continue on Nucleus Nexa Implant Launch

Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

William Demant Holding A/S / Equity Bottom-Up

<ul><li>Demant's latest financial results for 2024 reveal a mixed performance with several key developments influencing their overall outlook.</li><li>The company reported an overall growth in revenue of 4%, with an equal contribution from organic growth and acquisitions, amounting to DKK 22.4 billion.</li><li>While this marks an improvement in gross profit by 5%, the company's EBIT saw a decrease of about 2% (DKK 100 million) from the previous year, underscoring some challenges faced over the fiscal period.</li></ul>

Demant's latest financial results for 2024 reveal a mixed performance with several key developments influencing their overall outlook.The company reported an overall growth in revenue of 4%, with an equal contribution from organic growth and acquisitions, amounting to DKK 22.4 billion.While this marks an improvement in gross profit by 5%, the company's EBIT saw a decrease of about 2% (DKK 100 million) from the previous year, underscoring some challenges faced over the fiscal period.

Demant A/S: Initiation of Coverage- Can AI-Powered Hearing Tech Disrupt the Global Market?

<ul>
<li>
<a href="https://www.smartkarma.com/entities/cochlear-ltd" target="_blank" data-smartkarma-citation="entities:918:1" rel="noopener">Cochlear Ltd (COH AU)</a> now expects FY25 underlying net profit to be at the lower end of A$410–430M guidance range due to lower services revenue and higher cloud-related investment.</li>
<li>Despite 5% growth in H1FY25, Cochlear reiterated that “solid market growth rates to drive cochlear implant unit growth of around 10% in FY25.”</li>
<li>Cochlear is expected to release next-generation cochlear implant in mid-2025. The introduction of the new off-the-ear Nucleus Kanso 3 sound processor is expected to contribute to services revenue from FY26.</li>
</ul>



Cochlear Ltd (COH AU) now expects FY25 underlying net profit to be at the lower end of A$410–430M guidance range due to lower services revenue and higher cloud-related investment.
Despite 5% growth in H1FY25, Cochlear reiterated that “solid market growth rates to drive cochlear implant unit growth of around 10% in FY25.”
Cochlear is expected to release next-generation cochlear implant in mid-2025. The introduction of the new off-the-ear Nucleus Kanso 3 sound processor is expected to contribute to services revenue from FY26.


Cochlear Ltd (COH AU): Negative Reaction Is Overdone; Performance Reversal Is Imminent

<ul>
<li>
<a href="https://www.smartkarma.com/entities/cochlear-ltd" target="_blank" data-smartkarma-citation="entities:918:1" rel="noopener">Cochlear Ltd (COH AU)</a> shares rallied 30%+ over the last six months. Shares are trading at NTM P/E of 51.3x, versus other Australia-listed medical devices companies’ P/E of 23–32x.</li>
<li>The underlying business strength depicted by strong financial performance and guidance raise, and superior product offerings justify the pricey valuation.</li>
<li>Cochlear lifted FY24 net profit guidance to A$385–400M (+26–31% YoY) from A$355–375M. The company expects FY24 cochlear implant volume growth of 10–15% YoY.</li>
</ul>



Cochlear Ltd (COH AU) shares rallied 30%+ over the last six months. Shares are trading at NTM P/E of 51.3x, versus other Australia-listed medical devices companies’ P/E of 23–32x.
The underlying business strength depicted by strong financial performance and guidance raise, and superior product offerings justify the pricey valuation.
Cochlear lifted FY24 net profit guidance to A$385–400M (+26–31% YoY) from A$355–375M. The company expects FY24 cochlear implant volume growth of 10–15% YoY.


Cochlear Ltd (COH AU): Underlying Business Strength Justifies Superior Valuation

Denmark

Demant A/S develop, manufacture, and sell products and equipment that help people with hearing loss connect and communicate. The Company focus on hearing devices and implants, diagnostic instruments, and personal communication. Demant serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

William Demant Holding A/S (DEMANT DC)

Cochlear Ltd (COH AU): Earnings Recovery to Continue on Nucleus Nexa Implant Launch

Cochlear anticipates strong revenue growth in FY26 driven by new Nucleus Nexa System launch, with expected 11-17% increase in underlying net...

Tina Banerjee

Demant A/S: Initiation of Coverage- Can AI-Powered Hearing Tech Disrupt the Global Market?

Demant's latest financial results for 2024 reveal a mixed performance with several key developments influencing their overall outlook. The company...

Baptista Research

Cochlear Ltd (COH AU): Negative Reaction Is Overdone; Performance Reversal Is Imminent

Cochlear expects FY25 profit to be at the lower end of guidance range, but remains optimistic about maintaining 10% implant volume growth. The...

Tina Banerjee

Cochlear Ltd (COH AU): Underlying Business Strength Justifies Superior Valuation

Cochlear lifted FY24 net profit guidance 8% to A$385–400M (+26–31% YoY). The company expects FY24 cochlear implant volume growth of 10–15% YoY from...

Tina Banerjee

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Cochlear Ltd (COH AU): Earnings Recovery to Continue on Nucleus Nexa Implant Launch

​Cochlear anticipates strong revenue growth in FY26 driven by new Nucleus Nexa System launch, with expected 11-17% increase in underlying net...

Tina Banerjee

Demant A/S: Initiation of Coverage- Can AI-Powered Hearing Tech Disrupt the Global Market?

Demant's latest financial results for 2024 reveal a mixed performance with several key developments influencing their overall outlook. The company...

Baptista Research

Cochlear Ltd (COH AU): Negative Reaction Is Overdone; Performance Reversal Is Imminent

​Cochlear expects FY25 profit to be at the lower end of guidance range, but remains optimistic about maintaining 10% implant volume growth. The...

Tina Banerjee

Cochlear Ltd (COH AU): Underlying Business Strength Justifies Superior Valuation

Cochlear lifted FY24 net profit guidance 8% to A$385–400M (+26–31% YoY). The company expects FY24 cochlear implant volume growth of 10–15% YoY from...

Tina Banerjee

Cochlear anticipates strong revenue growth in FY26 driven by new Nucleus Nexa System launch, with expected 11-17% increase in underlying net...

Cochlear expects FY25 profit to be at the lower end of guidance range, but remains optimistic about maintaining 10% implant volume growth. The...